Parallax Volatility Advisers’s BridgeBio Pharma BBIO Stock Holding History

Parallax Volatility Advisers’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-25,000	Closed	-$1.91M	–	1474
2025 Q4	$1.91M	Hold	25,000	–	–	﹤0.01%	965
2025 Q3	$1.3M	Hold	25,000	–	–	﹤0.01%	1046
2025 Q2	$1.08M	Hold	25,000	–	–	﹤0.01%	1034
2025 Q1	$864K	Hold	25,000	–	–	﹤0.01%	1088
2024 Q4	$686K	Buy	+25,000	New	+$646K	﹤0.01%	1437
2023 Q3	–	Sell	-8,100	Closed	-$139K	–	2287
2023 Q2	$139K	Sell	8,100 -91,900	-92%	-$1.38M	﹤0.01%	1952
2023 Q1	$1.66M	Buy	+100,000	New	+$1.17M	﹤0.01%	1294

Other funds holding BBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DAM

Diamant Asset Management Ridgefield, Connecticut $147M AUM 25.76% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Parallax Volatility Advisers's BBIO Position: Q1 2026 in Review

Parallax Volatility Advisers sold out of BridgeBio Pharma (BBIO) in Q1 2026, closing a stake of 5,538 shares — an estimated $424K sold.

Parallax Volatility Advisers first reported a position in BBIO in Q1 2023 and held it in 6 quarters. The position peaked at $429K in Q4 2024. 458 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

Parallax Volatility Advisers reported no remaining BridgeBio Pharma position as of Q1 2026 after selling out during the quarter.
Parallax Volatility Advisers sold 5,538 BridgeBio Pharma shares in Q1 2026, an estimated $424K.
Parallax Volatility Advisers first reported a position in BridgeBio Pharma in Q1 2023 and held it in 6 quarters.
Parallax Volatility Advisers's BridgeBio Pharma position peaked at $429K in Q4 2024.
458 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Parallax Volatility Advisers's 13F filing for Q1 2026, filed 15 May 2026.